Susanne Crowe
Binger Str. 173
Ingelheim Am Rhein, RP 55218, Germany
Ingelheim Am Rhein, RP 55218, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials.
Journal: Journal of diabetes and its complications
Published: May 18, 2016
Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials.
Journal: Journal of diabetes and its complications
Published: February 18, 2016
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Journal: Diabetes, obesity & metabolism
Published: February 15, 2016
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
Journal: Diabetes & vascular disease research
Published: February 14, 2016
Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
Journal: Journal of diabetes investigation
Published: August 21, 2015
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: July 29, 2015
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Journal: Diabetes & vascular disease research
Published: May 06, 2015
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Journal: Postgraduate medicine
Published: April 05, 2015
Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD
Published: April 01, 2015
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Journal: Diabetes care
Published: February 17, 2015
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Journal: Clinical therapeutics
Published: April 30, 2014
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
Journal: Diabetes, obesity & metabolism
Published: December 06, 2013
Last Updated: 09/26/2026